Voyager - Homecoming #1 brings the crew back for one final mission. But can they truly go home again, or is there no place ...

A live webcast of the call will be available on the Investors section of the Voyager website at ir.voyagertherapeutics.com, and a replay of the call will be available at the same link ...

--Voyager Therapeutics, Inc., a gene therapy company developing life-changing treatments and next-generation adeno-associated virus capsids, today is scheduled to present findings demonstrating ...

Voyager Digital, now bankrupt as part of the crypto collapse of 2022, is in the news once again as the Commodities Futures Trading Commission (CFTC) has filed charges against its former CEO ...

LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics (VYGR), Inc. , a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report third ...

--Voyager Therapeutics, Inc. a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced it will report third quarter 2023 financial and operating ...

Two people on their laptops using the TESSAN Voyager 205BERLIN, Sept. 02, 2025 (GLOBE NEWSWIRE) -- TESSAN will debut the ...

Webcasts of the Citi and Baird fireside chats will be available and may be accessed from the Investors section of Voyager’s ...

CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today ...

– Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e13 vg/kg ...

Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases.

LEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report ...